Atypical teratoid/rhabdoid tumor of the central nervous system is a highly malignant neoplasm and that usually arises in the posterior fossa, survival from this is frequently poor. We present a unique case in a 21-month-old girl who had an atypical teratoid/rhabdoid tumor with cystic components located in the right fronto-parietal lobe. The patient underwent radical surgical intervention followed by chemotherapy. It consisted of five chemotherapeutic agents, but the patient did not receive any radiotherapy. The postoperative course was uneventful and the patient was followed-up by cranial magnetic resonance imaging every 3 months. Two years later at the last follow-up visit, there was no evidence of a tumor relapse on MRI, and the examination was symptom free. It is possible the favorable outcome of the patient resulted from a rapid diagnosis, prompt management, radical surgical intervention and aggressive chemotherapy.

1.
Lu L, Wilkinson EJ, Yachnis AT: CSF Cytology of atypical teratoid/rhabdoid tumor of the brain in a two-year-old girl: a case report. Diagn Cytopathol 2000;23:329–332.
2.
Rorke LB, Packer R, Biegel J: Central nervous system atypical teratoid/rhabdoid tumors of infancy and childhood. J Neurooncol 1995;24:21–28.
3.
Raisanen J, Hatanpaa KJ, Mickey BE, White CL: Atypical teratoid/rhabdoid tumor: cytology and differential diagnosis in adults. Diagn Cytopathol 2004;31:60–63.
4.
Rorke LB, Packer RJ, Biegel JA: Central nervous system atypical teratoid/rhabdoid tumors of the infancy and childhood: definition of an entity. J Neurosurg 1996;85:56–65.
5.
Chung YN, Wang KC, Shin SH, Kim N, Chi JG, Min KS, Cho BK: Primary intracranial atypical teratoid/rhabdoid tumor in a child: A case report. J Korean Med Sci 2002;17:723–726.
6.
Caldemeyer KS, Smith RR, Azzarelli B, Boaz JC: Primary central nervous system malignant rhabdoid tumor: CT and MR appearance simulates a primitive neuroectodermal tumor. Pediatr Neurosurg 1994;21:322–326.
7.
Horn M, Schlote W, Lerch KD, Steduel WL, Harms D, Thomas E: Malignant rhabdoid tumor: primary intracranial manifestation in an adult. Acta Neuropathol (Berl) 1992;83:445–448.
8.
Martinez-Lage JF, Nieto A, Sola J, Domingo R, Costa TR, Poza M: Primary malignant rhabdoid tumor of the cerebellum. Child Nerv Syst 1997;13:418–421.
9.
Agranovich AL, Ang LC, Griebel RW, Kobrisky NL, Lowry N, Tchang SP: Malignant rhabdoid tumor of the central nervous system with subarachnoid dissemination. Surg Neurol 1992;37:410–414.
10.
Hilden JM, Meerbaum S, Burger P, Finlay J, Janss A, Scheithauer BW, Walter AW, Rorke LB, Biegel JA: Central nervous system atypical teratoid/rhabdoid tumor: results of therapy in children enrolled in a registry. J Clin Oncol 2004;22:2877–2884.
11.
Beckwith JB, Palmer NF: Histopathology and prognosis of Wilm’s tumor: results from the first National Wilm’s tumor study. Cancer 1978;41:1937–1948.
12.
Tekautz TM, Fuller CE, Blaney S, Foulad M, Broniscer A, Merchant JE, Krasin M, Dalton J, Hale G, Kun LE, Wallace D, Gilbertson RJ, Gajgar A: Atypical teratoid/rhabdoid tumors (ATRT): Improved survival in children 3 years of age and older with radiation therapy and high-dose alkylator-based chemotherapy. J Clin Oncol 2005;23:1491–1499.
13.
Lee YK, Choi CG, Lee JH: Atypical teratoid/rhabdoid tumor of the cerebellum: Report of two infantile case. AJNR Am J Neuroradiol 2004;75:481–483.
14.
Arslanoglu A, Aygun N, Tekhani D, Arnoson L, Cohen K, Burger PC, Yousem DM: Imaging findings of CNS atypical teratoid/rhabdoid tumors. AJNR AMJ Neuroradiol 2004:476–480.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.